Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

62.28USD
19 Jan 2018
Change (% chg)

$0.45 (+0.73%)
Prev Close
$61.83
Open
$62.10
Day's High
$62.42
Day's Low
$61.56
Volume
7,490,267
Avg. Vol
5,571,759
52-wk High
$66.10
52-wk Low
$46.01

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.08
Market Cap(Mil.): $101,933.70
Shares Outstanding(Mil.): 1,636.70
Dividend: 0.40
Yield (%): 2.57

Financials

  Industry Sector
P/E (TTM): -- 33.09 17.86
EPS (TTM): -- -- --
ROI: -- 15.01 33.11
ROE: -- 16.57 17.05

BRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME

Jan 08 2018

Bristol-Myers sees $3 billion tax hit in fourth quarter 2017

Bristol-Myers Squibb Co will record a $3 billion charge in the fourth quarter of 2017 as a result of the U.S. tax reform law passed last month, the drugmaker said in a regulatory filing on Friday.

Jan 05 2018

Bristol-Myers sees $3 billion tax hit in fourth quarter 2017

Jan 5 Bristol-Myers Squibb Co will record a $3 billion charge in the fourth quarter of 2017 as a result of the U.S. tax reform law passed last month, the drugmaker said in a regulatory filing on Friday.

Jan 05 2018

BRIEF-Bristol-Myers Estimates Tax Reform To Result In Additional Net Tax Expense Of About $3 Bln In Q4

* BRISTOL-MYERS SQUIBB - ESTIMATES THE IMPACT OF U.S. TAX REFORM TO RESULT IN ADDITIONAL NET TAX EXPENSE OF ABOUT $3 BILLION IN THE FOURTH QUARTER OF 2017‍​

Jan 05 2018

BRIEF-Bristol-Myers Squibb Receives FDA Approval For Opdivo As Treatment For Patients With A Type Of Skin Cancer

* BRISTOL-MYERS SQUIBB RECEIVES FDA APPROVAL FOR OPDIVO (NIVOLUMAB) AS ADJUVANT THERAPY IN PATIENTS WITH COMPLETELY RESECTED MELANOMA WITH LYMPH NODE INVOLVEMENT OR METASTATIC DISEASE Source text for Eikon: Further company coverage:

Dec 20 2017

BRIEF-Taris And Bristol-Myers Squibb Announce Clinical Trial Collaboration

* TARIS AND BRISTOL-MYERS SQUIBB ANNOUNCE CLINICAL TRIAL COLLABORATION

Dec 20 2017

BRIEF-Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Yervoy (ipilimumab)

* BRISTOL-MYERS SQUIBB RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF YERVOY (IPILIMUMAB) FOR THE TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH UNRESECTABLE OR METASTATIC MELANOMA

Dec 18 2017

BRIEF-Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists

* Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs

Dec 13 2017

BRIEF-Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment

* BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT

Dec 13 2017

BRIEF-U.S. FDA Accepts Bristol-Myers Squibb’S Application For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab)

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AND GRANTS PRIORITY REVIEW

Dec 13 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $147.36 +0.44
Pfizer Inc. (PFE.N) $36.94 -0.05
Merck & Co., Inc. (MRK.N) $61.28 +0.15
Sanofi SA (SASY.PA) €72.95 +0.58
AstraZeneca plc (AZN.L) 5,043.00 +62.50
GlaxoSmithKline plc (GSK.L) 1,358.00 +4.80
Eli Lilly and Co (LLY.N) $85.49 -0.33
Roche Holding Ltd. (ROG.S) CHF234.50 +1.30
Roche Holding Ltd. (RO.S) CHF237.80 +1.00

Earnings vs. Estimates